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Hepatitis E virus (HEV) infection is gaining global attention, not only because of the increasing burden of the
disease in low endemicity countries, in terms of morbidity and mortality rates, but also due to recent advances
in the molecular virology and epidemiology of this emerging pathogen. HEV infection spread can be described
as the evolution of a zoonosis towards an established human infection. As known from other viruses, such as
the human immunodeficiency virus or the influenza viruses, crossing the species barriers from animals to
humans is a recurrent phenomenon. Albeit slow at the beginning, once the virus has adapted to humans,
the person-to-person spread can proceed very quickly. Although an optimal cell culture system for HEV is
not yet available, outstanding progress has been made with the in vitro expression of HEV-like particles.
These new tools have fostered new research to understand the molecular, structural and immunological
aspects of human HEV infection. Although some promising data from Phase II vaccine trials are available,
recent discoveries will certainly open new avenues for HEV-specific prophylaxis and therapy.
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Epidemiology
Hepatitis E virus (HEV) infection is arguably the most frequent
acute viral hepatitis infection around the world. The real global
burden of HEV infection is not established, but it is estimated
that one-third of the world population has been infected with
HEV.1 The global spread of HEV follows the socioeconomic
status of populations; thus, the seroprevalence is highest in
countries where water sanitation is poor. High endemicity
areas comprise: (i) Central and South East Asia, with .20% of
anti-HEV seroprevalence among the general population of
China, 45% in rural areas of Malaysia and .20% in India;2,3
and (ii) North Africa and the Middle East, with up to 26% in
Egypt and 17% in Saudi Arabia.4 In Western countries, the sero-
prevalence within the general population is 1%–3% in Europe
and 2% in the USA (with up to 20% in certain ethnic groups).
Accumulating evidence surrounding cases of HEV infection in
these countries suggests that they are due to autochthonous
viral strains (i.e. locally acquired),5–7 nearly always classified
as viral genotype 3. However, in these low-endemicity areas,
special groups, such as farmers, veterinarians, butchers and
persons handling animal meat or consumers of undercooked
swine/wild deer meat, present with a considerably higher sero-
prevalence than the general population. This is due to the fact
that HEV is mainly a zoonosis involving comestible animals,
such as wild boars, deer or domestic pigs. The meat of the
latter constitutes a substantial part of the human food chain,
and viral spread can occur through the ingestion of infected
and undercooked meat.8 Indeed, swine and human HEV strains
show extremely close genetic relatedness (especially HEV
genotypes 3 and 4, as discussed below). These observations
suggest, on the one hand, that animals may serve as a reservoir
for human HEV infection and, on the other hand, that current
human infection may originally derive from natural infection of
wild boars.9,10 The evolution from a zoonosis to a human infec-
tion is confirmed by reports showing the close relationship of
full genome sequence analyses of human and swine infections
for genotype 3 and 4 infections. Moreover, the routes of trans-
mission are very interesting. The most common route of trans-
mission of HEV is probably foodborne. This may occur either
through drinking water contaminated with faeces from infected
individuals or animals, or via ingestion of meat from infected
animals. In addition, parenteral spread, via blood products or
solid organ transplantation, has been well documented. In
fact, the blood supply is vulnerable to non-enveloped viruses
like HEV, because pathogen-inactivation methods are insufficient
and routine serological tests are not in place.11 Lastly, vertical
mother-to-child transmission, either intrauterine or perinatal,
has been described.12 Thus, these multifaceted routes of trans-
mission facilitate viral diffusion (and adaptation) to the human
species.
Clinical manifestations
The clinical manifestations of HEV infection span a large array of
symptoms, i.e. from a totally asymptomatic course to life-
threatening severe hepatitis with acute liver failure (ALF) and
elevated mortality. Endemic disease associated with genotype
1 or 2 infections in developing countries occurs commonly in
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young adults, whereas clinical hepatitis E associated with
infection with genotypes 3 or 4, as seen in industrialized
countries, peaks in patients ≥60 years of age.13 In most patients,
acute infection manifests after an incubation period of 3–
6 weeks, and is characterized by a subclinical to severe picture
of cholestatic hepatitis, with jaundice, anorexia, nausea, vomit-
ing and occasionally fever, lasting for 1–6 weeks. Severe, life-
threatening hepatitis with ALF may occur in 1% of cases, con-
sidered overall, in both high- and low-endemicity areas. However,
severe morbidity and mortality rates are highest in pregnant
women. In a recent retrospective study from India on ALF in
pregnancy, it was shown that a significantly higher proportion
of ALF was caused by HEV, but also that the overall outcome
of ALF in pregnant women was unrelated to the cause of the
disease.14 Thus, the mortality for ALF in HEV-infected pregnant
women (51%) was not higher than that in HEV-uninfected preg-
nant women (54%).
Until recently, it was believed that HEV was a self-limited
infection. However, persistent HEV infection accompanied by
chronic liver disease, in some rare cases progressing to cirrhosis,
has been described in immune-suppressed patients. In particu-
lar, different cases of HEV infection in solid organ transplant reci-
pients (liver, kidney or pancreas) have been reported with
persistent detection of HEV RNA in stools or serum up to
15 months after the acute infection.15–17 Liver histology may
show portal hepatitis with lymphocytic infiltrates and fibrosis,
with progression over time to cirrhosis even requiring retrans-
plantation of a liver graft in one case. Of note is another report
of a reactivation of HEV infection 3 months after complete recov-
ery and allogenic stem cell transplantation, leading to specu-
lation that the virus might persist in hepatocytes.18 Taken
together, these reports have changed our view on the natural
history of HEV infection. Persistent HEV infection, accompanied
by chronic, progressive liver damage that can evolve towards
cirrhosis, is an infrequent but clinically significant occurrence
in immune-suppressed patients.
Diagnosis
Diagnostic tools to assess HEV infection are available and
encompass serological assays to detect anti-HEV antibodies
capable of differentiating recent from past infection (IgG and
IgM). ELISA for antibodies to HEV genotypes 1–4 are commer-
cially available, and are based on the detection of antibodies
against the highly conserved and immunogenic capsid protein
[encoded by open reading frame (ORF)2]. These ELISA are
characterized by a broad activity and good reproducibility.
Some concerns have been raised on the specificity of these
assays, especially when assessing the HEV prevalence in
countries with low endemicity rates.19 It is, however, unlikely
that seroprevalence figures will change dramatically in the
future upon the introduction of new generation assays.
The appearance of anti-HEV-specific IgM without IgG indi-
cates very recent infection, whereas the presence of anti-HEV
IgG without IgM points towards past infection. Anti-HEV-specific
IgG are produced early in infection; thus, both IgG and IgM might
be detected together, indicating an early state of the infection.
Anti-HEV-specific IgA has been used in the past to define
acute infection, but its use today is questionable. Diagnosis in
immune-suppressed patients is more difficult, because in these
patients seroconversion can be late or even lacking
altogether.16,17 Anti-HEV antibodies are detectable 1–3 weeks
after acute infection of immune-competent persons (IgM and
IgG). On the contrary, in immune-suppressed patients, serocon-
version might be delayed by up to 6–10 months. Thus, if the
patient is immune suppressed, a combination of serology and
nucleic acid testing, the most sensitive test for acute or
ongoing HEV infection, should be used. Nested or real-time PCR
amplifying a 189 bp stretch located in ORF2 may detect viral
genomic RNA in serum or stools, especially in acute infection
and within the first week after exposure. However, the period
of detectable HEV RNA in serum may be short-lived (10–
30 days after the onset of symptoms), although faecal shedding
of the virus may last for up to 2–3 months.
Molecular biology
Hepatitis E virus is a small, spherical, non-enveloped virus and a
member of the Hepevirus genus. Initially, based on structural
similarities, HEV was classified as a Calicivirus. However, accord-
ing to phylogenetic analyses, HEV is now grouped apart in the
Hepeviridae family. This comprises the human and swine HEV,
which is further divided into 4 genotypes, and the avian HEV,
which probably should be classified in a genus distinct from
the mammalian HEV. Similarities and differences of Caliciviridae
and Hepeviridae are summarized in Table 1. Hepeviridae and
Caliciviridae can infect different animals and provoke diverse
disease patterns. For example, HEV infection in piglets
remains asymptomatic, whereas the avian HEV can cause the
hepatitis-splenomegaly syndrome in chickens, with increased
mortality. In the Caliciviridae family, the rabbit haemorrhagic
disease virus causes severe pulmonary haemorrhage and
extended liver necrosis, leading to up to 90% mortality in
infected animals.20 Of note is that a vaccine against avian HEV
has been developed to avoid pandemics that threaten the
chicken industry.21
Recent insights about the viral structure of HEV have led to
great advances in the understanding of the molecular and
immunological features of this virus. The viral genome is a
7.2 kb positive stranded linear RNA that contains three ORFs.
ORF1 encodes non-structural proteins, ORF2 encodes the viral
capsid, the target for humoral and cellular immunity, and ORF3
encodes a small non-structural phosphoprotein that interacts
at various levels with the cell physiology, thus contributing to
HEV replication and pathogenesis, and possibly accounting for
its role in in vivo infectivity.22
Because there is no closely related, well-characterized virus,
little is known about the structure, life cycle and pathogenic
mechanisms of HEV. Moreover, an efficient cell culture system
for HEV is still lacking. Even though Tanaka et al.23 succeeded
to establish a persistent viral replication of a genotype 3 strain
in human hepatoma and carcinoma epithelial cell lines, the
system was hampered by the production of insufficient
amounts of viral particles. Thus, the size and structure of infec-
tious virions can only be deduced based on electron microscopy
imaging, sucrose gradient measurements and knowledge of the
structural components. HEV particles appear spherical, with
indentations on the surface, with a diameter of 32–34 nm.
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The outer shell, composed of 60 capsid proteins with an
icosahedral symmetry, surrounds a single-stranded 7.2 kb RNA
genome.24–26
To overcome the current limitations, in vitro systems expres-
sing HEV-like particles have been developed. These baculovirus-
based expression systems have fostered new research avenues
to unravel the molecular, structural and immunological features
of HEV infection. In particular, the nucleocapsid protein encoded
by ORF2 is of particular interest. The N-terminus of this protein is
a signal peptide followed by an arginine-rich domain that is well
conserved. This capsid protein can be produced either in
Escherichia coli or in insect cells and expressed as HEV-like
particles by recombinant baculovirus. These virus-like particles
of the capsid protein, with protruding spikes on the surface,
can be analysed by cryoelectron microscopy and the crystal
structure can be studied. As a consequence, Guu et al.27 have
shown that the capsid protein contains three linear domains
(S, P1 and P2) that play different roles in organizing the icosahe-
dral capsid. The S domain forms the capsid shell, and P1 and P2
contain the receptor-binding domains; the highly exposed P2
domain probably plays an important role in immunogenicity
and virus neutralization. Using the same system, Yamashita
et al.28 have determined the crystal structure of HEV-like par-
ticles from a genotype 3 strain at a 3.5 A˚ resolution and found
differences in the folding of the capsid protein compared with
genotype 1. Furthermore, cellular receptor binding regions and
epitopes for neutralizing antibodies were identified in the
crystal structure of the HEV-like particles of the capsid protein.
This 3D structure provides valuable information for understand-
ing the mechanisms of virus entry and assembly. Lastly, Li
et al.29 studied the structure of the protruding domain of the
capsid protein (domain E2s). This region harbours the neutraliz-
ing antibody-binding site and it seems that its dissociation
abolishes antibody recognition. This domain appears to be
essential for viral–host interaction and the propagation of the
viral infection, and may be an important target for new antivirals.
Translational applications of the 3D structure
of the viral capsid protein
An open question remains: how can we treat severe HEV
infection today? Specific treatments are lacking and therapy is
supportive. However, since the majority of infections are self-
limited, specific interventions may be needed only in the infre-
quent severe, life-threatening cases. In ALF cases, an urgent
liver transplant should be considered. However, available data
about the outcome are scanty.30,31
An unresolved issue remains the treatment of persistent
infection (and hepatitis) in immune-suppressed patients.
Because chronic HEV infection has been reported only recently,
the optimal therapy has not yet been established. In one case
series from Kamar et al.,32 three patients with chronic HEV
after liver transplantation were treated with pegylated
interferon-a: two of them reached a sustained virological
response, while the third patient relapsed after the end of
treatment.
What about vaccines? A Phase II study in volunteers of the
Nepalese Army, organized by GlaxoSmithKline and the US
Army, showed promising results.33 The vaccine was a genotype
1 recombinant capsid protein buffered with aluminium hydrox-
ide. The vaccination afforded a good protection, with an efficacy
of 95% after three doses and 85.7% after two doses over a
median follow-up of 2.5 years. Another interesting vaccine is
the HEV 239, whose Phase II study results were reported
recently.34 Vaccine 239 is a recombinant HEV capsid protein
that is truncated to 239 amino acids, expressed in E. coli and
absorbed with aluminium hydroxide. The Phase II study evalu-
ated safety and immunogenicity with a dose-finding design.
With three doses of 10 mg or two doses of 20 mg, a 100% and
98% seroconversion rate was induced. Lastly, another vaccine
from France, tested so far only in mice, uses the above-described
approach of capsid protein expression in the baculovirus
system.35 HEV virus-like particles of the ORF2 gene products
Table 1. Similarities and differences of Caliciviridae and Hepeviridae
Caliciviridaea Hepeviridae
Phylogenetic
classification
Norwalk virus (NV) the human and swine HEV is further classified into four major
genotypes; the avian HEV should probably be classified in a
genus distinct from the mammalian HEV
Sapporo-like viruses (SV)
Rabbit haemorrhagic disease virus (LV)
European brown hare syndrome virus (LV)
Rabbit calicivirus (LV)
San Miguel sea lion virus (VV)
Vesicular exanthema of swine virus (VV)
Viral structure non-enveloped viruses with a single-stranded
positive-sense RNA genome having a size varying
between 7.3 and 8.3 kb
non-enveloped virus with a single-stranded positive-sense RNA
genome of 7.2 kb
Viral proteins two to three ORFs encoding structural and
non-structural proteins
three ORFs: ORF1 and 3 encode non-structural proteins, whereas
ORF2 encodes the major capsid protein
Capsid protein the capsid protein of both families has a highly exposed domain that is recognized by neutralizing antibodies; this protruding
region is structurally different among the viruses, but might have similar roles in the host–virus interaction
ORF, open reading frame.
aThe family of Caliciviridae is divided into four genera: Norovirus (NV); Sapovirus (SV); Lagovirus (LV); and Vesivirus (VV).
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(capsid protein) were injected intradermally into mice, either
directly or as human papillomavirus (HPV) type 31 virus-like par-
ticles. Two ORF gene products were used: one expressing amino
acids 112–660; and the other expressing amino acids 112–608.
The ORF2 virus-like particles (112–660) in the HPV 31 appeared
strongly immunogenic and evoked antibody responses in all
mice at very high titres.
Taken together, the recent advances in the knowledge of the
HEV life cycle and structural features of the HEV capsid protein,
obtained by crystallographic analyses, facilitate vaccine and
new drug developments. The next and even more difficult ques-
tion will be how and where to use such vaccines. Undoubtedly,
travellers from low-endemicity to higher endemicity areas
should be protected. However, a real issue is how feasible can
be a nationwide campaign in high-endemicity areas. Shouldn’t
the sanitation conditions be tackled first? Undoubtedly, a univer-
sal paediatric vaccination in high-endemicity countries would be
the best and most effective solution, but is this realistic? In the
most recent viral hepatitis reports of the WHO, it is emphasized
that HEV vaccines should be developed, but how a global
vaccine programme should be deployed is not discussed. And
yet, as in the case of other examples of zoonoses that became
human infections, the burden of HEV will certainly increase in
low-endemicity areas with both autochthonous and imported
viral strains.
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